Kestra Medical Technologies (NASDAQ:KMTS) Insider Timothy Moran Sells 8,759 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) insider Timothy Moran sold 8,759 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $22.61, for a total transaction of $198,040.99. Following the completion of the sale, the insider directly owned 68,725 shares of the company’s stock, valued at approximately $1,553,872.25. The trade was a 11.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Performance

NASDAQ:KMTS traded up $1.16 during mid-day trading on Monday, reaching $23.99. 373,728 shares of the company’s stock were exchanged, compared to its average volume of 404,856. Kestra Medical Technologies, Ltd. has a one year low of $14.10 and a one year high of $30.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The business’s fifty day simple moving average is $22.62 and its two-hundred day simple moving average is $22.48. The firm has a market capitalization of $1.41 billion, a PE ratio of -9.91 and a beta of 0.58.

Get Kestra Medical Technologies alerts:

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last posted its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The business had revenue of $28.64 million during the quarter. Analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KMTS has been the topic of a number of recent research reports. The Goldman Sachs Group lowered their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. BTIG Research increased their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Oppenheimer began coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating for the company. Finally, Wall Street Zen downgraded shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $27.83.

View Our Latest Report on Kestra Medical Technologies

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Seven Grand Managers LLC bought a new position in shares of Kestra Medical Technologies in the 4th quarter valued at $2,652,000. Eventide Asset Management LLC lifted its position in shares of Kestra Medical Technologies by 5.4% during the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after buying an additional 65,288 shares during the last quarter. Summit Partners Public Asset Management LLC acquired a new stake in Kestra Medical Technologies in the fourth quarter valued at about $9,282,000. Jennison Associates LLC boosted its stake in Kestra Medical Technologies by 15.0% in the fourth quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock valued at $5,817,000 after buying an additional 28,573 shares in the last quarter. Finally, UBS Group AG grew its position in Kestra Medical Technologies by 34.9% in the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after acquiring an additional 69,908 shares during the last quarter.

Kestra Medical Technologies Company Profile

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

Featured Articles

• Five stocks we like better than Kestra Medical Technologies
• SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
• Why Rare Earth Processing Could Be the Real 2027 Opportunity
• The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
• TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?

Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.